Financing ·
Addex Therapeutics reports CHF 3.5M net loss for H1 2026, raises USD 2.8M via ATM offering
ADXNAddex Therapeutics Ltd.
Addex Therapeutics reported a net loss of CHF 3.5 million for the first half of 2026, driven by operating expenses and a CHF 2.3 million share of losses from its Neurosterix equity investment. The company raised USD 2.8 million through an At-the-Market offering in August 2026. Addex regained rights to its GABAB PAM substance use disorder program from Indivior following their merger with Supernus Pharmaceuticals, while continuing preclinical development of a chronic cough candidate. Neurosterix is on track to complete Phase 1 trials for NTX-253 in schizophrenia by Q4 2026. The company operates as a clinical-stage biopharmaceutical firm developing small molecule allosteric modulators for neurological disorders.